Initial direct comparison of 99mTc-TOC and99mTc-TATE in identifying sites of disease in patients with proven GEP NETs

Journal of Nuclear Medicine

Volumn 49, Issue 7, 2008, Pages 1060-1065

  Cwikla, Jaroslaw B ^a,e   Mikolajczak, Renata ^b   Pawlak, Dariusz ^b   Buscombe, John R ^c   Nasierowska Guttmejer, Anna ^a   Bator, Andrzej ^a   Maecke, Helmut R ^d   Walecki, Jerzy ^a  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Ministry of Interior and Administration Republic of Poland Central Clinical Hospital   (Poland)

Author keywords

99mTc TATE; 99mTc TOC; GEP NET; Somatostatin receptor scintigraphy

Indexed keywords

CONTRAST MEDIUM; OCTREOTIDE[3 TYROSINE,8 THREONINE]; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; IMAGE QUALITY; MALE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY IMAGING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; FEMALE; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 46749090507     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.046961     Document Type: Article

References (14)

1. Reubi JC, Kvols L, Krenning EP, Lamberts SWJ. Distribution of somatostatin receptor in normal and tumour tissue. Metabolism. 1990;30(suppl 2):78-81.
2. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111-In-DTPA-D-Phe] and [123-I-tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
3. Behe M, Maecke HR. New somatostatin analogues labelled with technetium-99m. Eur J Nucl Med. 1995;22:791P.
4. 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27:628-637.
5. 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27:1318-1325.
6. 111In-octreotide. J Nucl Med. 2000;41:1114-1119.
7. 111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med. 2005;46:1561-1569.
8. 99mTc-EDDA/ HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006;33:1123-1133.
9. Plöckinger U, Rindi R, Arnold R, Eriksson B, Krenning EP, de Herder WW. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology. 2004;80:394-424.
10. 99mTc HYNIC TATE to evaluate patients with neuroendocrine tumours base on WHO classification [abstract]. J Nucl Med. 2005;43(suppl):410P.
11. 99mTc-EDDA/HYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment. Eur J Nucl Med Mol Imaging. 2006;33:1041-1047.
12. 111In-DTPA- octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708-716.
13. 99mTc-P829. Cancer Res. 1998;58:1850-1859.
14. Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am. 2007;21:561-573.